SCHEMBL6315166

SCHEMBL6315166

CC(C)CNC(=O)c1c(-c2ccco2)noc1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.60
NPC1 O15118 9/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
HPGD P15428 4/20 0.60
HTT P42858 1/20 0.60
ALDH1A1 P00352 6/20 0.45
GAA P10253 4/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GLA P06280 1/20 0.45
RUNX1 Q01196 1/20 0.45
MCL1 Q07820 1/20 0.45
CBFB Q13951 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 3/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6617667 0.89 RAB9A (0.47) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6315847 0.88 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6317940 0.85 TDP1 (0.45) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6316408 0.83 TSHR (0.45) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6322264 0.82 ALDH1A1 (0.55) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6318373 0.82 TDP1 (0.55) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6316732 0.82 RAB9A (0.59) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6316285 0.82 RAB9A (0.46) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6617134 0.82 ALDH1A1 (0.43) RAB9ANPC1SMN1; SMN2HPGDHTT
SCHEMBL6315889 0.81 ALDH1A1 (0.52) RAB9ANPC1SMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885NPC1 3741/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.